Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 vs investigator’s choice chemotherapy in HER2-low metastatic breast cancer
CTR20232959Phase 3Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab repodatecan in breast cancer, sponsored by Kanion Pharmaceutical. Started Dec 2023; status: active.
02
Drugs
anbenitamab repodatecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232959.